1
|
Zhang S, Wu K, Feng J, Wu Z, Deng Q, Guo C, Xia B, Zhang J, Huang H, Zhu L, Zhang K, Shen B, Chen X, Ma S. Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells. Oncotarget 2016; 7:68768-68780. [PMID: 27634890 PMCID: PMC5356588 DOI: 10.18632/oncotarget.11967] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2016] [Accepted: 08/24/2016] [Indexed: 12/13/2022] Open
Abstract
Metastasis is the reason for most cancer death, and a crucial primary step for cancer metastasis is invasion of the surrounding tissue, which may be initiated by some rare tumor cells that escape the heterogeneous primary tumor. In this study, we isolated invasive subpopulations of cancer cells from human non-small cell lung cancer (NSCLC) H460 and H1299 cell lines, and determined the gene expression profiles and the responses of these invasive cancer cells to treatments of ionizing radiation and chemotherapeutic agents. The subpopulation of highly invasive NSCLC cells showed epigenetic signatures of epithelial-mesenchymal transition, cancer cell stemness, increased DNA damage repair and cell survival signaling. We also investigated the epigenetic therapy potential of suberoylanilide hydroxamic acid (SAHA) on invasive cancer cells, and found that SAHA suppresses cancer cell invasiveness and sensitizes cancer cells to treatments of IR and chemotherapeutic agents. Our results provide guidelines for identification of metastatic predictors and for clinical management of NSCLC. This study also suggests a beneficial clinical potential of SAHA as a chemotherapeutic agent for NSCLC patients.
Collapse
Affiliation(s)
- Shirong Zhang
- Department of Oncology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou, China
| | - Kan Wu
- Department of Oncology, Affiliated Hangzhou First People's Hospital of Zhejiang Chinese Medical University, Hangzhou, China.,Department of Oncology, Hangzhou Cancer Hospital, Hangzhou, China
| | - Jianguo Feng
- Cancer Research institute, Zhejiang Cancer Hospital, Hangzhou, China
| | - Zhibing Wu
- Department of Oncology, Hangzhou Cancer Hospital, Hangzhou, China
| | - Qinghua Deng
- Department of Oncology, Hangzhou Cancer Hospital, Hangzhou, China
| | - Chao Guo
- Department of Cancer Genetics and Epigenetics, City of Hope National Medical Center, Duarte, CA, USA
| | - Bing Xia
- Department of Oncology, Hangzhou Cancer Hospital, Hangzhou, China
| | - Jing Zhang
- Department of Oncology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou, China
| | - Haixiu Huang
- Department of Oncology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou, China
| | - Lucheng Zhu
- Department of Oncology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou, China
| | - Ke Zhang
- Department of Oncology, Hangzhou Cancer Hospital, Hangzhou, China
| | - Binghui Shen
- Department of Cancer Genetics and Epigenetics, City of Hope National Medical Center, Duarte, CA, USA
| | - Xufeng Chen
- Department of Pathology and Laboratory Medicine, University of California at Los Angeles, Los Angeles, CA, USA
| | - Shenglin Ma
- Department of Oncology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou, China
| |
Collapse
|
2
|
Perri F, Lazzari G, Della Vittoria Scarpati G, Silvano G. Oral vinorelbine: a feasible and safe partner for radiotherapy in the treatment of locally advanced non-small cell lung cancer. Onco Targets Ther 2016; 9:2359-64. [PMID: 27143931 PMCID: PMC4846070 DOI: 10.2147/ott.s103645] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
Background Concurrent chemoradiotherapy (CCRT) using cisplatin-based doublets represents the standard of care for locally advanced non-small cell lung cancer (NSCLC), having shown good efficacy and activity in clinical trials. Locally advanced NSCLC occurs frequently in the elderly population, which is often excluded by platinum-based CCRT administration, due to severe associated toxicities. This limitation has been overcome using new-generation drugs such as gemcitabine, docetaxel, paclitaxel, and vinorelbine, which have shown not only to be efficacious but also to have a favorable toxicity spectrum, both in association with cisplatin and as single agents. Vinorelbine is a vinca alkaloid that binds to tubulin, thus inhibiting mitotic microtubule polymerization. Previous studies have clearly demonstrated that vinorelbine acts as a radiosensitizing agent when administered intravenously or orally. Moreover, oral administration of vinorelbine has shown a good clinical safety profile in both elderly and younger patients. Methods A comprehensive review of the literature data regarding use of oral vinorelbine concurrently with radiotherapy in NSCLC was done. Conclusion Single-agent oral vinorelbine may represent an effective therapy option for elderly patients with locally advanced lung cancer. This review has described the use of oral vinorelbine both as a monochemotherapy and in combination with cisplatin in the context of CCRT.
Collapse
Affiliation(s)
- Francesco Perri
- Radiation Oncology Department, San Giuseppe Moscati Hospital, Taranto, Italy
| | - Grazia Lazzari
- Medical Oncology Unit, San Giuseppe Moscati Hospital, Taranto, Italy
| | - Giuseppina Della Vittoria Scarpati
- Radiation Oncology Department, San Giuseppe Moscati Hospital, Taranto, Italy; Medical Oncology Unit, San Giuseppe Moscati Hospital, Taranto, Italy
| | - Giovanni Silvano
- Medical Oncology Unit, San Giuseppe Moscati Hospital, Taranto, Italy
| |
Collapse
|